Last reviewed · How we verify
Prophylaxis C
At a glance
| Generic name | Prophylaxis C |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention (NA)
- Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Tonsillectomy (NA)
- Talk With Me Baby: Leveraging Well-Child Care to Enhance the Early Home Language Environment (NA)
- Pilot Testing Suicide Risk Prediction Algorithms in Primary Care (NA)
- Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) (PHASE1, PHASE2)
- PREVENT Pilot HPV - Related Cancers Trial (NA)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prophylaxis C CI brief — competitive landscape report
- Prophylaxis C updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI